SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracle is trending after reporting strong Q3 earnings that surpassed expectations and significantly raising its FY27 revenue guidance, driven by accelerated cloud infrastructure growth and a massive backlog for AI services. The community is actively discussing how these results validate the surging demand for AI infrastructure, challenging prior skepticism about the company's financial strategy.

NIO, Inc. is a holding company which engages in the design, manufacture, and sale of electric vehicles. Its products include the EP9 supercar and ES8 7-seater SUV. It provides users with home charging, power express valet services, and other power solutions including access to public charging, access to power mobile charging trucks, and battery swapping. It also offers other value-added services such as service package, battery payment arrangement, and vehicle financing and license plate registration. The company was founded by Bin Li and Li Hong Qin on November 28, 2014 and is headquartered in Jiading, China.

NIO Inc - ADR

NIO Inc

NIO is trending after reporting a surprise fourth-quarter profit and solid guidance, which is fueling renewed bullish sentiment among the community regarding its innovative BaaS model, new chip development, and potential for a significant short squeeze.

UiPath, Inc. engages in the development and provision of a software platform to automate business processes. The firm serves the public, healthcare, telecommunication, finance, and banking industries. It also offers accounts payable automation, claims processing automation, contact center automation, and finance and accounting automation. The company was founded by Daniel Dines and Marius Tirca in 2005 and is headquartered in New York, NY.

UiPath Inc - Ordinary Shares - Class A

UiPath Inc

UiPath (PATH) is trending with high anticipation for its upcoming earnings, as its recent AIUC-1 certification highlights its role in secure enterprise AI agent orchestration. This fuels a polarized community debate between those expecting a significant short squeeze and fundamental strength in Agentic AI, and bears concerned about competition and valuation.

Terrestrial Energy, Inc. is an advanced nuclear technology company focused on next-generation nuclear energy systems. The company is developing the Integral Molten Salt Reactor (IMSR), an innovative type of Generation IV molten salt reactor designed to produce reliable, low-carbon heat and electricity at competitive costs. The company is headquartered in Charlotte, NC.

Terrestrial Energy Inc.

Terrestrial Energy (IMSR) is trending following new DOE agreements for its Integral Molten Salt Reactor technology and a $15 price target from Northland Securities. This sparks community debate over its 'dark horse' potential to power AI data centers and its competitive standing against nuclear sector peers like OKLO.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

USO is trending amid extreme volatility driven by conflicting reports concerning the Strait of Hormuz, including a retracted official claim of a US Navy escort and unconfirmed intelligence of Iranian mine deployment. This has sparked intense community debate on market manipulation versus genuine supply risks within the ongoing geopolitical conflict.

Groupon, Inc. engages in the global scaled two-sided marketplace that connects consumers to merchants. It operates through the North America and International geographical segments. The company was founded by Andrew D. Mason, Eric Paul Lefkofsky, and Bradley A. Keywell in October 2008 and is headquartered in Chicago, IL.

Groupon Inc

Groupon (GRPN) is trending amid mixed Q4 earnings results that, despite some misses, marked a return to billings and revenue growth for the first time in a decade, fueling heated debate as community skepticism about its core business battles strong conviction among bulls highlighting its significant stake in the fintech unicorn SumUp and the potential for a massive short squeeze.

Polaryx Therapeutics, Inc. engages in the manufacturing of biotechnology products. Its pipeline of products includes PLX-100, PLX-200, and PLX-300. The company was founded by Hahn-Jun Lee on August 22, 2014 and is headquartered in Paramus, NJ.

Polaryx Therapeutics Inc.

Polaryx Therapeutics (PLYX) is experiencing extreme volatility following its recent direct listing and a massive pre-market price spike, with traders actively discussing its low float and high cost-to-borrow as potential drivers for a short squeeze. Despite being an unprofitable clinical-stage biotech focused on rare diseases, the community is debating its short-term momentum versus long-term dilution risks.

goeasy Ltd. engages in the provision of non-prime leasing and lending services. The company was founded by Gordon J. Reykdal on December 14, 1990 and is headquartered in Mississauga, Canada.

Goeasy Ltd

Goeasy Ltd. is experiencing significant volatility and community discussion following its decision to suspend dividends and withdraw its financial outlook, reigniting concerns about subprime lending risks and management's past statements. Investors are sharply divided between those foreseeing a deep decline amid talks of potential lawsuits and others viewing the dramatic pullback as an oversold buying opportunity.

NANO Nuclear Energy, Inc. is a microreactor and nuclear technology company, which provides supply energy services. Its products in technical development are ZEUS, a solid core battery reactor, and ODIN, a low-pressure coolant reactor. The company is founded by Jiang Yu in February, 2022 and is headquartered in New York, NY.

Nano Nuclear Energy Inc.

NANO Nuclear Energy is a focal point of market discussion following recent operational milestones, including a new MOU for microreactor deployment in South Korea and the commencement of drilling for its KRONOS MMR system. The company also benefits from the dismissal of a federal lawsuit and a feasibility study for a 1 GW Texas power project, all contributing to the broader bullish sentiment for nuclear energy as a solution for surging AI data center power demands.

Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. Its product portfolio is heavily focused on innovative prescription medicines, especially oncology, immunology, neuroscience, and cardiovascular diseases, supplemented by established older brands and a wide range of specialized therapies. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Novartis AG - ADR

Novartis AG

Novartis is trending following multiple significant FDA approvals for its innovative medicines, including Scemblix and Fabhalta, and a series of strategic acquisitions to bolster its pipeline in oncology, immunology, and rare diseases. The company's substantial investment in U.S. manufacturing and an upgraded sales outlook underscore its assertive strategy to drive future growth.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

D. Boral Capital Reiterates Buy Rating for Estrella Immunopharma (NASDAQ:ESLA)

D. Boral Capital reissued a "buy" rating and issued a $8.00 price target on shares of Estrella Immunopharma in a research report on Monday...

Estrella Immunopharma Presents Promising Updated Data on EB103 in Oral Presentation at the 2026 Tandem Meetings of ASTCT & CIBMTR

Estrella Immunopharma, Inc. (Nasdaq: ESLA, ESLAW) (Estrella or the Company), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies to treat cancer and...

Estrella Immunopharma Announces Late-Breaking Oral Presentation of Phase 1 STARLIGHT-1 Data for EB103 at the 2026 Tandem Meetings of ASTCT & CIBMTR

Estrella Immunopharma, Inc. (Nasdaq: ESLA) (Estrella or the Company), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies to treat cancer and...

Estrella Immunopharma, Inc. Announces $8.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules

Estrella Immunopharma, Inc. (NASDAQ: ESLA) (the Company), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies to treat cancers and autoimmune...

Short Interest in Estrella Immunopharma, Inc. (NASDAQ:ESLA) Grows By 28.5%

Estrella Immunopharma, Inc. (NASDAQ:ESLA - Get Free Report) saw a large increase in short interest in the month of December. As of December 15th, there was short interest totaling 709,318 shares, an...

Estrella Immunopharma (NASDAQ:ESLA) Trading 1.3% Higher - Here's Why

Estrella Immunopharma (NASDAQ:ESLA) Trading 1.3% Higher - What's Next...

Estrella Advances STARLIGHT-1 Trial into Phase II Following Positive DSMB Recommendation

Estrella Immunopharma, Inc. (NASDAQ: ESLA) (Estrella or the Company), a clinical stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies to treat cancer and...

Estrella Immunopharma (NASDAQ:ESLA) Raised to "Hold" at Wall Street Zen

Wall Street Zen upgraded Estrella Immunopharma to a "hold" rating in a research note on Saturday...

Candel Therapeutics Inc. (13% jump in followers)Candel Therapeutics Inc. shares gained momentum as Wall Street analysts&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/cadl-stock-jumps-on-canaccord-buy-rating/ch5uUlPRwp">highlighted</a> the potential of its lead cancer drug candidate, CAN-2409. Canaccord expects continued clinical success in prostate, pancreatic, and non-small cell lung cancer, noting a significant increase in median overall survival in testing so far. Citi’s modeling suggests CAN-2409 could extend survival in localized prostate cancer by as much as eight to nine years over radiotherapy alone.&nbsp;The stock is up over 35% year-to-date.Acelyrin Inc. (12% jump in followers)Acelyrin confirmed that Concentra Biosciences, controlled by Tang Capital Partners, submitted an unsolicited offer to acquire all outstanding shares of Acelyrin for $3.00 per share in cash, plus a contingent value right tied to future licensing or asset sales.Earlier in the month, Acelyrin announced a merger agreement with Alumis in an all-stock transaction expected to close in the second quarter of 2025, pending shareholder approval.&nbsp;Acelyrin stock is down over 18% year-to-date.Solid Biosciences Inc. (11% jump in followers)Solid Biosciences shares surged after early-stage data from its gene therapy candidate SGT-003 for Duchenne muscular dystrophy&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/sldb-stock-soars-on-dmd-trial-data/ch5rNeJRvt">showed</a> promising results.&nbsp;Following the data release, Chardan raised its price target on the stock and increased the therapy’s probability of success to 48%, citing strong early efficacy signals and manageable safety risks.Solid Biosciences stock is up 43% year-to-date.Estrella Immunopharma Inc. (11% jump in followers)Estrella Immunopharma received a bullish initiation from D. Boral Capital, which started coverage with a ‘Buy’ rating and a $16 price target. The firm sees Estrella as a potential major player in immuno-oncology, with its EB103 therapy using ARTEMIS T-cell engineering technology to target solid tumors.&nbsp;The company also completed the first dose cohort in its Phase I/II trial, receiving approval from the Data and Safety Monitoring Board to proceed to the second dose level.&nbsp;Estrella stock is up over 22% year-to-date.Aditxt Inc. (10% jump in followers)Aditxt announced that its subsidiary, Pearsanta, has engaged Dominari Securities as the lead underwriter for its planned initial public offering. The IPO aims to support Pearsanta’s U.S. and international commercial launch of its Mitomic Technology platform for early cancer detection.&nbsp;Pearsanta is developing a non-invasive blood test to detect cancer at earlier stages by leveraging mitochondrial DNA deletions as biomarkers. IPO proceeds will fund the U.S. launch of its Laboratory Developed Tests (LDTs) and drive global commercialization through distribution partnerships and regulatory approvals.&nbsp;Aditxt stock is down over 53% year-to-date.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Woman examining laboratory samples - stock photo | Image source: Getty Images

Top 5 Biotech Stocks That Saw Biggest Retail Following Jump Last Week

Investors on Stocktwits flocked to these five biotech stocks last week, ending Feb. 21, 2025, driven by buyout buzz, bullish analyst calls, and promising clinical developments.

Equity

Investors on Stocktwits flocked to these five biotech stocks last week, ending Feb. 21, 2025, driven by buyout buzz, bullish analyst calls, and promising clinical developments.


Estrella Immunopharma, Inc. operates as a pre-clinical stage biopharmaceutical company, which engages in the development of T-cell therapies for patients with cancers and autoimmune diseases. The company was founded on March 30, 2022 and is headquartered in Emeryville, CA.

Current Price	$1.22
Prev Close	$1.12
Open	$1.14
Dividend Yield	0.00%
50-Day Moving Average	$1.20
Beta	0.69
Avg. Volume	408,568.08
PE Ratio	-3.03

52-Week High	$3.15
52-Week Low	$0.7301
Market Capitalization	$47.08M
EPS (Annual)	-$0.2425
Price to Book	-4.30
Revenue Per Employee	N/A

ESLA
Estrella Biopharma Inc

Feed

News

Sentiment

Fundamentals

Info

Latest ESLA News

ESLAEstrella Biopharma Inc